We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Three acute treatments for migraine — Eli Lilly’s Reyvow (lasmiditan), Biohaven’s rimegepant, and Allergan’s Ubrelvy (ubrogepant) — may not be cost-effective, according to the Institute for Clinical and Economic Review (ICER). Read More
Biogen has agreed to purchase Pfizer’s early-stage neurological disease drug for $75 million plus royalties and up to $635 million in future payments. The acquisition of PF-05251749 marks the latest move by Biogen into potential treatments for neurological diseases. Read More
The European Commission has approved AbbVie’s $63 billion acquisition of Allergan on condition that the companies sell off Allergan’s investigational treatment for inflammatory bowel disease (IBD). Read More
The FDA hit a Rockledge, Florida over-the-counter drugmaker with a warning letter over failures related to testing, quality unit oversight and water quality monitoring. Read More
A bipartisan drug pricing bill currently awaiting a vote on the Senate floor could have unintended consequences for generics, according to the Association for Accessible Medicines. Read More
Bristol-Myers Squibb and Sanofi have filed a complaint against the state of Hawaii over a lawsuit that seeks massive fines against the drugmakers for failing to include a warning in labeling for their anti-blood clotting drug Plavix (clopidogrel). Read More